Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2023

Open Access 01-12-2023 | Cancer Immunotherapy | Correction

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials

Authors: Xianjing Chu, Wentao Tian, Ziqi Wang, Jing Zhang, Rongrong Zhou

Published in: Molecular Cancer | Issue 1/2023

Login to get access

Excerpt

Correction: Mol Cancer 22, 93 (2023) …
Literature
1.
Metadata
Title
Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Authors
Xianjing Chu
Wentao Tian
Ziqi Wang
Jing Zhang
Rongrong Zhou
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2023
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-023-01812-z

Other articles of this Issue 1/2023

Molecular Cancer 1/2023 Go to the issue

Review

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Review

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

Correspondence

A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma

Review

Targeting Pim kinases in hematological cancers: molecular and clinical review

Research

Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma

Retraction Note

Retraction Note: m6A modification-mediated CBX8 induction regulates stemness and chemosensitivity of colon cancer via upregulation of LGR5
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits